钠-葡萄糖共转运体-2 抑制剂是 1 型糖尿病幼儿胰岛素治疗期间的安全辅助药物吗？首例 SLC5A2 基因突变的 1 型糖尿病患者。

IF 3 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Pub Date : 2024-06-26 DOI:10.1111/1753-0407.13570

Mohamad Ahangar Davoodi, Mohammad Ali Daneshmand, Taraneh Rezaei

引用次数: 0

摘要

亮点儿童 1 型糖尿病患者在出现低血糖的同时还伴有持续性糖尿，这需要进一步评估。早晨低血糖是钠葡萄糖转运体 2（SGLT2）抑制剂对 5 岁以下儿童的副作用。作为 SGLT2 抑制剂的 SLC5A2 突变可使年幼儿童的糖化血红蛋白在可接受的范围内，并降低所需的胰岛素剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation

查看原文本刊更多论文

Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation

Highlights

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Diabetes ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

2.20%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation. The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and will solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content.